🇺🇸 FDA
Patent

US 10066228

Oligonucleotides for treating expanded repeat diseases

granted A61PA61P21/02A61P21/04

Quick answer

US patent 10066228 (Oligonucleotides for treating expanded repeat diseases) held by Sarepta Therapeutics, Inc. expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P21/02, A61P21/04, A61P25/14, A61P25/28